Image pharmaphorum Editor Debates & Insight Sponsored Disruption and maturity: the future directions for biologics Is the UK’s NHS saving enough from the new wave of biosimilars? Debates & Insight Sponsored Powering pharma’s commercial teams with market access insigh... Debates & Insight Sponsored Powering the life sciences commercial engine with market acc... Views & Analysis Clinical trials: realising the untapped potential Winning proposal to create a corporate social responsibility (CSR) programme. Load more results
Debates & Insight Sponsored Disruption and maturity: the future directions for biologics Is the UK’s NHS saving enough from the new wave of biosimilars?
Views & Analysis Clinical trials: realising the untapped potential Winning proposal to create a corporate social responsibility (CSR) programme.
News Eisai unveils digital platform for kidney cancer patients Eisai has launched a 'digital destination', called Kompass, that aims to support patients after they have been given a diagnosis of kidney cancer.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
